APUS
***Sponsored by Primetime Profiles, LLC
Hello Everyone,
Yesterday's profile exploded pretty quick and saw as much as 18% during the session. We have something we feel is right in a zone where it could bounce after recent movement. Pull up APUS. Apimeds Pharmaceuticals is a clinical-stage biotech company dedicated to advancing non-opioid, biologic therapies for pain relief.
Traditional biotech companies often follow a familiar pattern—burning significant amounts of cash, diluting shareholders through repeated funding rounds, and racing toward commercialization. Apimeds is pursuing a different strategy. Through its merger with MindWave, the company has incorporated a digital asset platform designed to generate returns alongside conventional funding sources, with the goal of reducing dilution while continuing to advance its clinical programs.
MindWave’s digital asset model is built on three key components: secure corporate BTC custody solutions that allow institutions to safely hold and manage Bitcoin reserves, AI-driven yield strategies designed to generate returns within controlled risk parameters, and a validator-based ecosystem supported by the $NILA token, which creates additional revenue opportunities beyond basic treasury management. As part of this integration, approximately 1,000 BTC has been allocated into a structured treasury framework focused on preserving capital while producing returns to support ongoing research and development.
This approach allows Apimeds to maintain full independence of its pharmaceutical operations, ensuring that its clinical work remains the primary focus, while the digital asset platform serves as a complementary engine for growth and value creation. The company is supported by a recently completed $100 million PIPE financing, providing the capital needed to advance both its therapeutic pipeline and digital infrastructure.
At the same time, Apimeds is approaching several near-term clinical milestones, including a planned Biologics License Application submission following its confirmatory osteoarthritis trial and the initiation of a Phase 3 study for multiple sclerosis-related pain. Notably, these programs are expected to require less than $12 million in total capital, representing a relatively efficient path compared to typical late-stage biotech development.
The activation of its 1,000 BTC treasury further demonstrates the operational readiness and scalability of the MindWave platform. This strategy is unfolding alongside broader market trends, including increasing demand for non-addictive pain treatments amid the ongoing opioid crisis, growing institutional adoption of Bitcoin as a treasury asset, and currently compressed biotech valuations that may present timely opportunities.
By combining large market opportunities in osteoarthritis and MS pain with capital-efficient development, diversified value creation through digital assets, clearly defined near-term milestones, and strong institutional backing, Apimeds is positioning itself differently from traditional biotech firms. Rather than fitting squarely into either biotech or fintech, the company integrates elements of both. With financing secured, its digital treasury in place, and clinical programs progressing, Apimeds has established a foundation for its next phase of growth.
More than 32 million people in the U.S. live with osteoarthritis, while millions of others suffer from severe pain linked to multiple sclerosis—without any approved treatment options. For years, patients have had to choose between imperfect solutions: NSAIDs that carry cardiovascular risks, corticosteroids with significant side effects, costly biologics with inconsistent outcomes, or opioids that contribute to a widespread addiction crisis claiming tens of thousands of lives each year.
The demand for better options is clear. The U.S. osteoarthritis treatment market alone was valued at $8.28 billion in 2022 and is expected to grow to over $20 billion by 2032.
Apimeds Pharmaceuticals (NYSE: APUS) sits at the crossroads of this urgent medical need and a new model for biotech financing.
After completing its merger with MindWave Innovations Inc. and securing $100 million through a PIPE financing, the company now operates a distinctive dual-platform structure:
Advanced Non-Opioid Pain Therapy Pipeline
Apitox, derived from honeybee venom, introduces a new approach to targeting inflammation and immune responses—offering potential where traditional treatments have fallen short.
AI-Powered Digital Asset Treasury
MindWave contributes an institutional-grade digital asset platform combining secure BTC treasury management, AI-driven yield strategies, and a validator-based ecosystem supported by the $NILA token.
Clinical Opportunity
Efficient Pathway to Commercialization
Apitox for Knee Osteoarthritis
Apimeds already holds Phase 3 data for Apitox in knee osteoarthritis, one of the most widespread and underserved pain conditions. A confirmatory study is expected to cost under $10 million—significantly less than typical late-stage biotech programs.
If successful, the company plans to submit a Biologics License Application (BLA) to the FDA, marking the final regulatory step before entering a market approaching $20 billion.
Apitox for MS-Related Pain
An even more compelling opportunity lies in multiple sclerosis pain, where no FDA-approved therapies currently exist.
Apimeds holds rights to an FDA-cleared Investigational New Drug (IND) application for a Phase 3 trial. The study design is simple: a single-site trial involving 25–35 patients to confirm pain reduction during MS flare-ups. Early anecdotal evidence is encouraging, and the study is expected to cost under $2 million.
This represents a true “blue ocean” opportunity—an unmet need with no direct competition and a defined regulatory path.
What Sets Apitox Apart
Compared to traditional treatments, Apitox offers:
- A unique mechanism based on the therapeutic properties of honeybee venom
- An option for patients who haven’t responded well to existing therapies
- Access to a largely untapped space in inflammation and immune modulation
- A foundation rooted in toxin-based therapies, which have a track record of success
Rather than being just another pain medication, Apitox aims to fill a critical gap in treating complex, chronic conditions.
NEWS
1 day ago
Mar 25, 2026
Mar 24, 2026
Feb 11, 2026
Dec 17, 2025
Dec 10, 2025
Dec 1, 2025
Nov 10, 2025
Oct 14, 2025
Sep 15, 2025
Dec 1, 2025
Nov 10, 2025
Oct 14, 2025
Sep 15, 2025
MANAGEMENT
Dr. Vin Menon
Chief Executive Officer and Director
Dr. Vin Menon is a veteran in the technology services industry, who can be credited with the strategic direction behind several disruptive technology companies. In the corporate world, he has held various leadership positions at multinational corporations like HP & Compaq with global responsibilities. Driven by his passion for technology and innovation, Dr. Menon has been a forerunner in technological innovation and has helped create the business ecosystem of disruptive technologies and high-growth companies. His experience has helped him in the technology space as an entrepreneur and advisor, leading several startups from inception to meteoric growth across continents. Dr. Menon’s proven track record of setting up motivated and high caliber teams in the technology and services industry, establishing development centers from scratch to scale, and building company competencies led him to being awarded ‘Entrepreneur of the Year 2012’ by Rotary-ASME, ‘Outstanding Entrepreneur Award 2011’ by APEA, the ‘Spirit of Enterprise 2010’ by SOE Singapore. Dr. Menon was also selected as a ‘Leading Indian Entrepreneur of the Year 2010’ by the Singapore Indian Chamber of Commerce.
From the years 2021 to 2023 he co- founded and served as Strategic Advisor to CGCX, a Fintech, decentralized finance, and digital assets platform, where he provided strategic advisory services and growth initiatives. He currently serves as Chief Executive Officer of AQUAE Impact (AQUAE Impact Exchange Co. L.L.C / AQUAE Impact), a sustainable financial and environmental assets platform that uses blockchain technology and artificial intelligence, which he co-founded and currently forms part of its executive leadership providing oversight of product and sustainability initiatives. He also currently serves as Chief Executive Officer of AQUAE Labs Pte Ltd, which is the research and development and technology arm of AQUAE Impact, where he provides product and technology leadership, measurement, reporting, and verification of environmental credits. Additionally, he currently occupies the role of Strategic Advisor of TechyTrade FZ-LLC, which is a bitcoin-backed company that operates in the digital asset and treasury innovation space. Dr. Menon is also a champion of techno-preneurship and was serving on the Board of Directors of the Spirit of Enterprise (SOE) and the Mentoring Programme under Action Community for Entrepreneurship (ACE) by SPRING Singapore. Moreover, he completed his bachelor’s degree in computer applications from India, with first-class honors. He has also completed the following programs: Advanced Management Program (AMP) at NTU-Berkeley (Haas Business School, California) and Advanced Management Program (AMP) at The Wharton School (University of Pennsylvania, USA) specialized in Finance. Dr. Menon obtained an EMBA from the Nanyang Technological University (NTU) in Singapore. Lastly, he completed his PhD, Blockchain for Impact in Healthcare from The Open International University for Complementary Medicine in collaboration with Al-Farabi Kazakh National University, Kazakhstan 2019.
We believe that these experiences provide Dr. Menon with the skills necessary to lead the Company as its Chief Executive officer and members of the board, including overseeing the Company’s strategy, operations, financial performance, and overall corporate governance.
Sungjoon Chae
Co-Chief Executive Officer
Sungjoon Chae was named co-CEO in May 2026. He is a Strategic Principal Architect and Urban Designer with a distinguished background in leading large-scale architectural and planning initiatives. Leveraging a Master of Architecture in Urban Design from Harvard University, he possesses deep expertise in urban revitalization and spatial planning. He is recognized for steering cross-functional teams and delivering design excellence in competitive markets.
Erick J. Frim
Chief Financial Officer
Mr. Frim has over 40 years of experience as an accountant, financial executive and consultant. He joined Helio Corporation in December 2024. In 2019, he joined CFO Squad and as a partner in the CFO Squad, LLC Mr. Frim advised clients on technical accounting and regulatory compliance, assisting numerous companies with their initial public offerings. Prior to the CFO Squad, Mr. Frim served as a director in the public company audit practice of EisnerAmper LLP. Mr. Frim as also served as a financial executive for digital media pioneer DIVA Systems Corporation. A former CPA, he has a BS in Accounting from Ball State University.
Dr. Christopher Kim, MD
Chief Medical Officer
Dr. Christopher Kim has been our Chief Medical Officer since our inception and served as our interim Chief Executive Officer from July 2022 to September 2023.
Dr. Kim is the inventor and developer of Apitox and the founder of Apimeds Korea, where he has served as a director since its inception. Mr. Kim served as the Chief Executive Officer of Apimeds Korea from May 2003 to August 2011. Prior to founding Apimeds Korea, Dr. Kim lead with the support of Guju Pharmaceuticals, clinical trials for Apitoxin in Korea, which was approved by the Korea Food and Drug Administration in 2003 for relief of pain and inflammation for patients with Osteoarthritis. In 2005, he began focusing on the clinical development of Apitox in the United States, including the first of two-Phase III clinical studies for Osteoarthritis. Prior to his time with Apimeds Korea, Dr. Kim served as the President of the International Pain Institute of New Jersey from January 1983 to May 2003, a center for chronic pain and other disabling diseases that conducted clinical research and provided treatment. He served as a professor at Biomedical Center, CHA Graduate School of Medicine in Korea from March 2005 to February 2017.
Dr. Kim is a licensed physician in New Jersey, New York and Korea and a Pain Medicine Specialist (American Board). Over the past twenty years, Dr. Kim has treated thousands of chronically disabled patients with autoimmune diseases, including MS. Dr. Kim received his medical degree from the School of Medicine, CN University in Korea.
Susan Kramer, DrPH
Senior Vice President, Development
Susan Kramer has more than 30 years' experience in biopharmaceutical research and development, with the first 18 at Genentech. She was a co-founder of Corthera, Inc., subsequently acquired by Novartis, and has held senior management and key alliance management roles at a number of biotech companies, including XOMA, Anesiva and Annexon Biosciences. She most recently served as Executive Vice President of Development at Concentric Analgesics. She has led development teams for both protein and small molecule therapeutics in the US and globally.
Dr. Kramer received a BA from College of St. Scholastica, an MA in Education from Central Michigan University and earned her MPH and DrPH in Biomedical Sciences (Virology) from the University of California Berkeley. She has served on numerous science and education boards and committees.
Brian Peters
Senior Vice President, ai² Division
Brian Peters is a senior commercial executive with over 30 years of experience in global branding, business development, and product launches across neurology, rheumatology, hematology, cardiology and rare diseases. Most recently, he served as Chief Strategy & Insights Officer at Heller Agency, leading strategic planning, business development, and market positioning. Prior to that, he spent over a decade at Medexus Pharma, where he oversaw U.S. marketing and sales efforts, launched multiple products, and led a high-performing sales and marketing team that drove significant market share growth. He played an instrumental role in the acquisitions of IXINITY, Grafapex, and Gleolan, expanding Medexus’ U.S. portfolio.
Mr. Peters has held senior marketing and commercial leadership roles at Chiesi USA, Accera, Gilead Sciences, Biovail Pharmaceuticals, and G.D. Searle, playing a pivotal role in product commercialization, marketing strategy, and sales leadership.
He serves on the Future Pharma and PM360 Editorial Advisory Boards and is a frequent speaker at pharmaceutical conferences. Mr. Peters holds a B.A. in Communications from Indiana University Bloomington and is currently a board member of the non-profit organization Cardz for Kidz.
Sincerely,
Disclaimer:
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
O22 HAS BEEN COMPENSATED A FEE OF TWENTY FIVE THOUSAND USD BY A THIRD PARTY, PRIMETIME PROFILES, LLC FOR A ONE DAY APUS PROFILE ON 5/6/26.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.